A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
Items 301–400 of 576
Garcia-Toro, M., Aguilar-Latorre, A., Garcia, A., Navarro-Guzmán, C., Gervilla, E., Seguí, A., Gazquez, F., Marino, J. A., Gomez-Juanes, R., Serrano-Ripoll, M. J., et al. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1008891 · Cited by 10
“The inclusion criteria were: (Fava, 2003) 18 years old or older; (Mrazek et al., 2014) having a diagnosis of MDD based on the DSM-5 and Mini-International Neuropsychiatric Interview (MINI) criteria (Ferrando et al.”
BackgroundMethodThe cost-of-illness and burden-of-disease of treatment-resistant depression in Austria
Walter, E., Traunfellner, M., Gleitsmann, M., Zalesak, M., & Helmenstein, C. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2264718 · Cited by 14
Beaglehole, B., Glue, P., Clarke, M., & Porter, R. (2023) · BJPsych Open · doi:10.1192/bjo.2023.577 · Cited by 14
Wong, S. M. Y., Leung, D. K. Y., Liu, T., Ng, Z. L. Y., Wong, G. H. Y., Chan, W. C., & Lum, T. Y. S. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06281-2 · Cited by 15
“Aside from its long-term impact on the functioning and quality of life of affected individuals and their families and peers [5, 6], the longitudinal course of depression also inflicts considerable burdens on the healthcare system and economy, particularly if untreated or not fully treated [7–9].”
Treatment of anxiety symptoms in patients receiving rTMS for treatment resistant depression
Tuinstra, D., Percifield, C., Stilwell, K., Plattner, A., Edwards, E., Sanders, W., & Koval, M. (2021) · Psychiatry Research Communications · doi:10.1016/j.psycom.2021.100014 · Cited by 10
Münchenberg, P. S., Joyce, E. M., Matthews, K., Christmas, D. M., & Zrinzo, L. U. (2022) · Brain Sciences · doi:10.3390/brainsci12101379 · Cited by 11
“Although most patients respond to a combination of standard therapies (psychotherapy, pharmacotherapy, and, in more severe cases, electroconvulsive therapy), up to onethird may not respond adequately [3] and suffer from treatment-refractory depression (TRD).”
BackgroundJoshi, K., Cambron‐Mellott, M. J., Costantino, H., Pfau, A., & Jha, M. K. (2023) · Brain and Behavior · doi:10.1002/brb3.3143 · Cited by 9
Derosa, S., Misztak, P., Mingardi, J., Mazzini, G., Müller, H. K., & Musazzi, L. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110871 · Cited by 14
Forman‐Hoffman, V. L., Sihvonen, S., Wielgosz, J., Kuhn, E. R., Nelson, B. W., Peiper, N. C., & Gould, C. E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.057 · Cited by 12
Rengasamy, M. L., McClain, L. L., Gandhi, P., Segreti, A. M., Brent, D. A., Peters, D. G., & Pan, L. A. (2018) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2018.05.001 · Cited by 10
Opinion paper: poor response to treatment of depression in people in high occupational levels
Mandelli, L., Serretti, A., Porcelli, S., Souery, D., Mendlewicz, J., Kasper, S. F., Montgomery, S., & Zohar, J. (2018) · Psychological Medicine · doi:10.1017/s003329171800288x · Cited by 10
He, Y., Xu, L., Li, Y., Tang, Y., Rao, S., Lin, R., Liu, Z., & Chen, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104769 · Cited by 10
Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports
Arandjelovic, K., Eyre, H. A., & Lavretsky, H. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.05.010 · Cited by 11
Konder, R., & Christie, T. (2019) · Healthcare Policy | Politiques de Santé · doi:10.12927/hcpol.2019.26073 · Cited by 9
“In addition, 12–20% of depression cases may be treatment resistant (Mrazek et al. 2014), which would qualify some mental illnesses as both “grievous” and “irremediable.””
BackgroundArnaud, A. M., Benner, J., Suthoff, E. D., WERNEBURG, B. G., Reinhart, M. L., Sussman, M., & Kessler, R. C. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.147 · Cited by 11
Temporary Stoppages and Burden of Treatment in Patients With Cancer
Vachon, E. A., Given, B. A., Given, C. W., & Dunn, S. (2019) · Oncology nursing forum · doi:10.1188/19.onf.e135-e144 · Cited by 10
“, 2013), number of medications (Lhuilier, Brugeilles, & Rolland, 2015; Mrazek et al., 2014), number of interactions with healthcare providers (Cheng & Levy, 2017; Henry et al.”
Descriptive analysis of the economic burden of treatment resistance in a major depressive episode
Cai, Q., Sheehan, J. J., Wu, B., Alphs, L. D., Connolly, N., & Benson, C. J. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1671087 · Cited by 10
Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients
Jablonski, M. R., Lorenz, R. A., Li, J., & DeChairo, B. (2019) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988719892341 · Cited by 9
“Overall, mental illness follows cancer and cardiovascular disease as the third most expensive medical condition in the United States,(1) with increased costs associated with TRD.(3) Pharmacogenomic (PGx) testing aims to reduce the number of neuropsychiatric medication trials a patient undergoes.”
BackgroundInfluentialKanekar, S., Sheth, C. S., Ombach, H., Brown, J., Hoffman, M. D., Ettaro, R., & Renshaw, P. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05902-y · Cited by 11
Krupa, D., Czech, M., Pinkas, J., & Mosiołek, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042135 · Cited by 12
Adherence to evidence-based treatment guidelines for depression: a systematic review
Dizet, S., Haffen, É., & Javelot, H. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07192-6 · Cited by 15
“Depressive disorder can have a profound effect on all aspects of life, including performance at school, productivity at work, relationships with family and friends [1, 2].”
Rifkin-Zybutz, R. P., MacNeill, S., Davies, S., Dickens, C. M., Campbell, J., Anderson, I. M., Chew-Graham, C. A., Peters, T. J., Lewis, G., Wiles, N., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120965939 · Cited by 8
“Clarifying effective treatment for patients with treatment-resistance in primary care is key, as these patients are a common group that suffer from poorer quality of life, are harder to manage and utilize substantial healthcare resources (Mrazek et al., 2014).”
BackgroundDiMarzio, K., Parent, J. M., Forehand, R., Thigpen, J. C., Acosta, J., Dale, C. F., & Compas, B. E. (2021) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2021.1894943 · Cited by 10
“Depression is an important public health concern, with a lifetime prevalence of approximately 21% (Hasin et al., 2018) and an annual cost of over $100 billion in the United States alone (see Mrazek et al., 2014 for a review).”
BackgroundNeurocircuitry underlying the antidepressant effect of retrograde facial botulinum toxin in mice
Ni, L., Chen, H., Xu, X., Sun, D., Cai, H., Wang, L., Tang, Q., Hao, Y., Cao, S.-X., & Hu, X. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00964-1 · Cited by 8
“However, up to 20% of patients with MDD do not respond to existing antidepressants [4], which can also be associated with delayed therapeutic response and negative side effects.”
BackgroundBiomarkers for Major Depressive Disorder: Economic Considerations
Bogavac‐Stanojević, N., & Lakić, D. (2016) · Drug Development Research · doi:10.1002/ddr.21330 · Cited by 8
“MDD affects both the patient quality of life and society well-being with lost productivity and a high utilization of health-care resources, [Birnbaum et al., 2010; Mrazek et al., 2014].”
BackgroundTerstege, D. J., MacDonald, D. S., & Tasker, R. A. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.2 · Cited by 10
Shah, D., Zheng, W., Allen, L., Wei, W., LeMasters, T., Madhavan, S., & Sambamoorthi, U. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1900088 · Cited by 9
Perugi, G., Calò, P., Filippis, S. D., Rosso, G., Vita, A., Adami, M., Ascione, G., Morrens, J., & Delmonte, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.769693 · Cited by 9
Paschali, M., Kiss, O., Zhao, Q., Adeli, E., Podhajsky, S., Müller‐Oehring, E. M., Gotlib, I. H., Pohl, K. M., & Baker, F. C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.002 · Cited by 9
“Given that depression exerts a major personal, societal, and economic burden (Petito et al., 2020; Mrazek et al., 2014), there is an urgent need to identify more accurate risk factors for the development of this disorder in youth.”
BackgroundScarante, F. F., Lopes, V. D., Fusse, E. J., Vicente, M. A., de Abreu, G. H. D., Nardini, V., Sorgi, C. A., Lirio, P. H. C., Guo, F., Lu, H., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110894 · Cited by 8
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 8
Zhang, H., Li, X., Pang, J., Zhao, X., Cao, S., Wang, X., Wang, X., & Li, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00493 · Cited by 8
Vara, M. D., Mira, A., Miragall, M., García-Palacios, A., Botella, C., Gili, M., Riera-Serra, P., García-Campayo, J., Mayoral-Cleries, F., & Baños, R. M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17218094 · Cited by 7
“Major depressive disorder (MDD) is one of the most prevalent mental disorders worldwide, and it is associated with significant personal and social costs [1,2].”
BackgroundChen, L., Ye, T., Wang, X., Han, L., Wang, T., Qi, D., & Cheng, X. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220831152959 · Cited by 8
Yamagishi, A., Ikekubo, Y., Mishina, M., Ikeda, K., & Ide, S. (2024) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2024.01.008 · Cited by 7
Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression.
Singh, A., Brooks, M., Voorhees, R., Potter, M. A., Roberts, M., Luther, J., & Wisniewski, S. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201500448 · Cited by 9
Transcranial Magnetic Stimulation: A Clinical Primer for Nonexperts
Minzenberg, M., & Yoon, J. H. (2020) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000490 · Cited by 7
Toro-Pagán, N. M. D., Matos, A., Thacker, D. L., Turgeon, J., Amin, N. S., & Michaud, V. (2021) · Medicina · doi:10.3390/medicina57090955 · Cited by 8
“In 2012, a literature review reported that patients who have an inadequate response to their antidepressant regimen are expected to spend approximately USD 10,000 more annually on healthcare-related expenses than patients who have an adequate response [30].”
BackgroundCigognini, M. A., Guirado, A. G., van de Meene, D., Schneider, M. A., Salomon, M. S., de Alexandria, V. S., Adriano, J. P., Thaler, A. M., Fernandes, F. D. S., Carneiro, A. M., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.830301 · Cited by 9
Huang, W., Chiang, C. N., Wu, C., Liao, S., Chien, T. H., Tseng, C.-H., & Tang, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.114 · Cited by 7
The lived experience of major and treatment-resistant depression in England: a mixed-methods study
Kerr, C., Denee, T. R., Vincent, S.-A., Bailey, K. M., Young, A. H., Rathod, S., Desai, M. A., Baldock, L., & Jacobsen, N. (2023) · Acta Psychologica · doi:10.1016/j.actpsy.2023.104035 · Cited by 10
Deciphering deep brain stimulation for depression
Bhati, M. T., & Halpern, C. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30396-6 · Cited by 7
Definition and Epidemiology of Treatment Resistance in Psychiatry
Smith-Apeldoorn, S. Y., Veraart, J. K. E., & Schoevers, R. A. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_1 · Cited by 11
Wu, B., Cai, Q., Sheehan, J. J., Benson, C. J., Connolly, N., & Alphs, L. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220763 · Cited by 8
Park, H., Park, C. M., Woo, J., Shin, J., Lee, E., & Kwon, S. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1918922 · Cited by 8
Zhdanava, M., Karkare, S. U., Pilon, D., Joshi, K., Rossi, C., Morrison, L., Sheehan, J. J., Lefèbvre, P., Lopena, O. J., & Citrome, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01862-z · Cited by 6
Anhedonia in Major Depressive Disorder: Exploration of a Predictive Clinical Phenotype
Rizvi, S. J. (2015) · TSpace (University of Toronto) · Cited by 11
Caldieraro, M. A., Tung, T. C., Baena, L. M. A., Vilapriño, M., Corral, R. M., de la Serna, L. D. A., Uribe, E. S., KANEVSKY, G. A., & Cabrera, P. (2022) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2022.06.002 · Cited by 6
Roll, S. C., & Hahn, M. (2022) · Journal of Xenobiotics · doi:10.3390/jox12040022 · Cited by 7
Koeser, L., Rost, F., Gabrio, A., Booker, T. L., Taylor, D., Fonagy, P., Goldberg, D. P., Knapp, M. R. J., & McCrone, P. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.109 · Cited by 10
von Mücke-Heim, I.-A., Pape, J. C., Grandi, N. C., Erhardt, A., Deussing, J. M., & Binder, E. B. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01647-1 · Cited by 7
“TRD patients use health services more frequently and generate high healthcare costs, both at the absolute level as well as proportionally to the overall costs related to depression [27–29].”
BackgroundBeaglehole, B., Porter, R., Douglas, K. M., Lacey, C. J., de Bie, A., Jordan, J., Mentzel, C., Thwaites, B., Manuel, J., Murray, G., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084844 · Cited by 9
Kim, T. T., Xu, C., & Amsterdam, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.02.003 · Cited by 6
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges
Ghaznavi, S., & Richter, S. G. (2025) · Drugs · doi:10.1007/s40265-025-02172-2 · Cited by 10
Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression
Widge, A. S., Malone, D. A., & Dougherty, D. D. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16302 · Cited by 8
Oliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N. J., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250987 · Cited by 9
“TRD has a greater patient and societal burden than non-treatment resistant MDD, including lower health-related quality of life (HRQoL) and increased work and activity impairment (4, 9, 10).”
BackgroundValvassori, S. S., Varela, R. B., Resende, W. R., Possamai‐Della, T., Borba, L. A., Behenck, J. P., Réus, G. Z., & Quevedo, J. (2023) · Current Neurovascular Research · doi:10.2174/0115672026277345240115101852 · Cited by 7
Treatment-Resistant Depression Among US Military Veterans
Lande, R. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-05384-0_7 · Cited by 6
Pańczyk, K., Pytka, K., Jakubczyk, M., Rapacz, A., Siwek, A., Głuch‐Lutwin, M., Gryboś, A., Słoczyńska, K., Koczurkiewicz, P., Ryszawy, D., et al. (2019) · ChemistrySelect · doi:10.1002/slct.201902648 · Cited by 8
Selinheimo, S., Gluschkoff, K., Kausto, J., Turunen, J., Koskinen, A., & Väänänen, A. (2023) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-023-02523-y · Cited by 22
Lachaab, M. (2024) · Journal of Public Mental Health · doi:10.1108/jpmh-12-2023-0108 · Cited by 10
Ma, Z., Yu, Y., Gao, M., Chen, P., Hong, H., Yu, D., Liang, Z., Bai, Y., Ye, Q., Wang, Y., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00081 · Cited by 5
Bonetto, G. G., Corral, R. M., Lupo, C., Vilapriño, M., Alessandria, H., KANEVSKY, G. A., & Cabrera, P. (2022) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v33i155.134 · Cited by 10
Magnetic seizure therapy for treatment-resistant depression
Jiang, J., Li, C., Chen, Z., Cao, X., Wang, H., Li, W., & Wang, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013528 · Cited by 5
Chen, Y., Lyu, D., Wang, F., Huang, Q., Yang, W., Zhang, M., Wei, Z., Shi, S., Kong, S., Chen, S., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04465-2 · Cited by 6
Evaluation, Treatment, and Referral of Treatment-Resistant Depression in Primary Care
Chopra, A., Luccarelli, J., Cohen, J. N., Mischoulon, D., & Stern, T. A. (2023) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.22f03438 · Cited by 6
Medication-free Alternatives for Long-term Maintenance of Bipolar Disorder: A Case Series
Gurevich, M. I., & Robinson, C. L. (2015) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2014.064 · Cited by 6
Han, X.-M., Huang, F., Jiao, M., Liu, H., Zhao, Z., Zhan, H., & Guo, S. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00093 · Cited by 5
Foster, S. L., Petrie, S. R., Mischoulon, D., & Fava, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_8 · Cited by 6
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson, S. T., Ostroff, R. B., Katz, R. B., & Krystal, J. H. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_16 · Cited by 5
Junkes, L., Gherman, B. R., Appolinario, J. C., & Nardi, A. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303967 · Cited by 4
“Patients with this condition, particularly the subgroup with Treatment Resistant Depression (TRD), present a greater challenge due to the severity of their symptoms, longer duration of illness, high rates of recurrence and comorbidities, and increased mortality [3,4].”
Background6-Gingerol exerts antidepressant effect through regulating the PPARγ signaling pathway
Cheng, F.-Z., Wang, F., Hao, K.-J., Gao, Y., Zhang, J.-G., Zhang, F., & Wang, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177943 · Cited by 5
Shan, M., Zhang, J., Yang, F., Cao, F., Yang, Y., Li, W., & Wang, L. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04593-7 · Cited by 8
“Glabridin, a flavonoid compound isolated from licorice, exhibits well-documented anti-inflammatory, antioxidant, and neuroprotective activi - ties [27–29].”
Akram, A., Al‐Sabahy, M., Al-Jedai, A. H., Almudaiheem, H., Farghally, M., Fallata, E. O., Alibrahim, O. A., Shoukry, T. M., Basu, S., Chalouhi, D., et al. (2022) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1952 · Cited by 3
Göke, K., Downar, J. H., Vila‐Rodriguez, F., Daskalakis, Z. J., Rajji, T. K., Mulsant, B. H., & Blumberger, D. M. (2025) · Psychological Medicine · doi:10.1017/s0033291725102079 · Cited by 4
“TRD not only leads to increased disability rates, higher medical costs, and worse long-term outcomes but also contributes tofurther declines inQoL (Fekadu et al., 2009; Johnston et al., 2019; Mrazek et al., 2014; Rizvi et al., 2014).”
Teng, C.-T., Caldieraro, M. A., Lacerda, A. L. T., Nardi, A. E., Quarantini, L. C., Souza, F., Corrêa, H., KANEVSKY, G. A., & Cabrera, P. (2021) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v13.n3.p310-21 · Cited by 5
Nie, J., Zhang, Y., Wang, B., Wu, H., Chang, Z., Ren, Q., Zheng, J., Zhao, D., & Fang, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202405832 · Cited by 6
Hongler, K., Lounici, A., Maurer, E., Lanz, U., Szathmári, O., Reuter, Y., Nussbaum, S., Steinborn, I., Haedrich, A., Mölling, M. A., et al. (2024) · NeuroImmunoModulation · doi:10.1159/000542979 · Cited by 9
Optimization of antidepressant treatment by pharmacogenomics: a case report
Zhang, Y., & Yue, W. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06481-4 · Cited by 4
“A 2012 review study showed that patients who failed to respond adequately to antidepressant medications had healthcare-related expenditures that were approximately $10,000 more per year than those who responded effectively [14].”
Brexpiprazole: a step forward for precision medicine in resistant depression
Serretti, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528233 · Cited by 4
“Annual costs for healthcare and lost productivity were estimated to be much higher for patients with TRD versus patients with treatment-responsive depression [3].”
BackgroundChen, F. (2018) · International Journal of Pharmacy and Chemistry · doi:10.11648/j.ijpc.20180403.11 · Cited by 4
“Before determining that a patient is nonresponsive to an initial trial of antidepressants, he or she should be reassessed to confirm the accuracy of the diagnosis, medication adherence, and whether the depression is being exacerbated by coexisting medical, psychiatric, or psychosocial disorders.[3] Major depressive di…”
BackgroundAn Overview of Machine Learning Applications in Mood Disorders
Topolski, N., Jeong, S. H., & Mwangi, B. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.017 · Cited by 4
Leserri, S., Amil, A. S., Nowacki, A., Debove, I., Petermann, K., Schäppi, L., Preti, M. G., Ville, D. V. D., Pollo, C., Walther, S., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01683-x · Cited by 6
“Claudio Pollo, Sebastian Walther, and T. A. Khoa Nguyen have contributed equally to this work. treatment-resistant depression (TRD), a particularly debilitating subcategory of MDD [5].”
BackgroundMaier, H. B., Neyazi, A., Bundies, G. L., Meyer-Bockenkamp, F., Bleich, S., Pathak, H., Ziert, Y., Neuhaus, B., Müller, F.-J., Pollmann, I., et al. (2024) · Trials · doi:10.1186/s13063-024-08061-5 · Cited by 11
“Consequently, patients endure prolonged or chronic illness, leading to considerable personal and societal burden associated with the disease [8, 9].”
BackgroundExperimental Therapies for Treatment-Resistant Depression
Jha, M., & Trivedi, M. (2018) · Focus · doi:10.1176/appi.focus.20180013 · Cited by 6
Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside
Cai, M., Wang, H., & Zhang, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_15 · Cited by 7
Chen, Y., Huang, H., Zhi, K., ZHANG, S., Lin, Q., Qingya, W. A. N. G., & An, W. (2020) · Advances in Psychological Science · doi:10.3724/sp.j.1042.2020.01713 · Cited by 6
“…林秋韵 王庆娅 安 蔚 (重庆大学公共管理学院, 重庆 400044) 摘 要 抑郁症不仅严重影响个体的身心健康 , 也加大了医疗保健的负担 , 已成为全球关注的公共卫生问 题。众多研究表明昼夜节律紊乱与抑郁症显著相关, 使睡眠时型成为探讨抑郁发生和发展的一个新视角。睡 眠时型包括清晨型、中间型和夜晚型。夜晚型是抑郁的风险因素, 清晨型则是其保护性因素。情绪调节行为 机制和杏仁核、扣带回皮质等神经机制的探讨, 可以帮助我们更好理解睡眠时型对抑郁的影响。未来研究还 需要探索睡眠时型的多维结构, 增加前瞻性队列研究设计, 丰富心理和生理机制, 加强干预性的实证研究。 关键词 抑郁;…”
Hahn, M., & Roll, S. C. (2022) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00054 · Cited by 5
Miller, O. H., Grabole, N., Wells, I., & Hall, B. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/254904 · Cited by 4
“With this increased confidence in the relevance of the remaining DTGs, we selected target proteins to study further based on the following criteria: The target (1) is pharmacologically tractable, (2) has a favorable prediction for side effects based on previously published data (tissue expression pattern and known phe…”
MethodYaeger, J. D. W., John, M. M., Ledesma, L. J., Krupp, K. T., Booth, C. D., Jones, N., Valiño, A., Popp, N., Sathyanesan, M., Newton, S. S., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110558 · Cited by 3
“One third of patients are treatment-resistant (fail to respond to two or more antidepressants), and moreover, 23% of suicide victims are on an antidepressant at the time of death (Al-Harbi, 2012; David A. Mrazek et al., 2014; Gerhard et al., 2016).”
Genetics and Neurobiology of Treatment-Resistant Depression—A Review
Płaza, O., Gałecki, P., Bliźniewska-Kowalska, K. M., Gałecka, M., Brońska, A., Jornet-Plaza, J., Szurek, A., & Szulc, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211016 · Cited by 8
“This subtype of depression impacts not only patients and their loved ones, but is also a socioeconomic challenge, as it is related to increased risk of relapse, higher suicidality, and bigger socioeconomic costs [3].”
Panconesi, D., Murtough, S., Cotic, M., Khani, N. S., Varney, L., Richards-Brown, M., Abidoph, R., Mills, D., Richards‐Belle, A., Molai, J., et al. (2026) · The Pharmacogenomics Journal · doi:10.1038/s41397-025-00394-x · Cited by 5
“And the cost of managing non-responders to antidepressant treatment is around 10,000 USD/ year/patient greater than it is for managing responsive patients [13].”
Ribeiro, R. B., Generoso, M. B., Taiar, I., Lord, A. E. D. C., Netto, G. T. M., Gomes, J. S., Garrocini, L. P., Maranhão, M. F., de Araujo, M. A. A., da Silva, S. M. A. C., et al. (2023) · Jornal Brasileiro de Psiquiatria · doi:10.1590/0047-2085000000429 · Cited by 4
Promoting Adherence to a Yoga Intervention for Veterans With Chronic Low Back Pain
Gonzalez, C., Chang, D. G., Rutledge, T., & Groessl, E. J. (2025) · Global Advances in Integrative Medicine and Health · doi:10.1177/27536130251323247 · Cited by 3
Health Economics: The Hidden Costs of Mental Illness
Martini, D. R., & Attallah, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-12665-0_1 · Cited by 3
Treatment‐resistant depression: An overview for psychiatric advanced practice nurses
Kameg, B., & Kameg, K. M. (2020) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12596 · Cited by 4
“2 In a 3 ‐ year period, 8.1% of adults in the United States met diagnostic criteria for MDD. 3 Certain populations are more susceptible to MDD, with estimates showing that women are twice as likely than men to meet diagnostic criteria.”
InfluentialYoussef, N. A., McCall, W. V., Ravilla, D., McCloud, L., & Rosenquist, P. B. (2020) · Brain Sciences · doi:10.3390/brainsci10120979 · Cited by 3
Mood Disorders: Brain Imaging and Therapeutic Implications
(2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018 · Cited by 3
Application of Pharmacogenomics Testing in a Community-based Facility
Wang, J., Paul, S., Arbet, R. N., & Lin, A. C. (2022) · Hospital Pharmacy · doi:10.1177/00185787221134693 · Cited by 5
“Steps 1-2 Step 1: PGx test ordered—Step 2: PGx test result available to providers (n = 86)† 5 3 (1-23) 66 (76.”
BackgroundPredicting Poor Outcomes Among Individuals Seeking Care for Major Depressive Disorder
Liberman, J. N., Pesa, J. A., Rui, P., Teeple, A., Lakey, S. L., Wiggins, E., & Ahmedani, B. K. (2022) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20220011 · Cited by 4
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.